TX-FLUENCE
7.4.2022 15:02:07 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, released results from its intercanopy lighting research in collaboration with Wageningen University & Research (WUR). Fluence’s research showed that intercanopy lighting treatments at a high intensity combined with top light increased yield in Hi Power and Skyson cucumber cultivars as well as Merlice and Brioso tomato cultivars.
Following Fluence’s multiyear research on the overall effects of broad-spectrum lighting solutions on plant development, Fluence and WUR further investigated the effects of various light distributions and intensities on plant morphology and fruit quality throughout a winter season.
“Growers have used the same benchmarks for vine crop lighting strategies for decades. Those benchmarks were typically derived from crops grown under high-pressure sodium fixtures that limited potential light intensity due to excess heat,” said David Hawley, principal scientist for Fluence. “LEDs virtually eliminate that restriction. As Fluence seeks to explore how to empower growers to be as productive as possible by maximizing their bottom lines, we wanted to investigate not only how higher intensities affect crops, but how crops use energy within the canopy. Our research overwhelmingly showed that intercanopy lighting in tandem with a top light strategy at a higher intensity boosted yields over conventional lighting strategies.”
Fluence and WUR studied cucumbers and tomatoes in the Netherlands under four light treatments: top light only at 250 µmol/m-2 /s-1 , top light and intercanopy lighting at 250 µmol/m-2 /s-1 , top light only at 375 µmol/m-2 /s-1 , and top light and intercanopy lighting at 375 µmol/m-2 /s-1 . Under the treatments with both top light and intercanopy lighting, two-thirds of the total PPFD were applied to the top of the canopy with Fluence’s VYPR luminaire, with the other third applied through Fluence’s VYNE intercanopy light.
Key findings from the studies include:
- Adding intercanopy lighting at the higher total intensity increased cumulative yield in both cucumber cultivars up to 110% compared to the top light-only treatment at the lower intensity.
- Similarly, adding intercanopy lighting at the higher total intensity enabled a less aggressive pruning strategy that, in combination with the higher light intensity, also increased the cumulative number of cucumber fruits in both cultivars up to 53% compared to the top light-only treatment at the lower intensity.
- Both cucumber cultivars also saw a decrease in total plant height and more compact morphology at the higher intensity treatments.
- Adding intercanopy lighting at the higher total intensity also increased cumulative yield and the total number of fruits up to 62% and 57%, respectively, in both tomato cultivars over the top light-only treatment at the lower intensity.
To ensure high-quality crops year-round, cucumber and tomato greenhouse growers often explore supplemental lighting strategies to adequately light plants during darker fall and winter months. With Fluence and WUR’s latest intercanopy lighting research, growers can now consider additional light distribution options to optimize yield and quality to meet their cultivation goals.
For more information on Fluence and its ongoing research initiatives, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom